Pharma still guessing on Brexit – but more confident of avoiding no-deal

10 December 2019
brexit_credit_depositphotos_large

The guessing game about when, how and if the UK will exit the European Union (EU) goes on, with the views of pharma professionals still showing a range of predicted outcomes.

GlobalData’s Brexit tracker has been updated to reflect the latest views of these professionals, who will likely have an eye on the UK election this week to see what the next stage in the long saga is likely to be.

A fourth extension on the horizon?

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical